Budesonide/Formoterol Use During Pregnancy

Safety Profile of Components

Budesonide is the preferred inhaled corticosteroid (ICS) during pregnancy with the most safety data and is classified as FDA Pregnancy Category B, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
At usual doses, budesonide has not been associated with increased risk of major malformations, intrauterine growth restriction, preterm delivery, or low birth weight, as reported by the European Respiratory Society 3
Limited human data exists on formoterol use during pregnancy, but animal data suggest low risk, as noted by the European Respiratory Society 3
If a woman was well-controlled on formoterol before pregnancy, it is acceptable to continue with the same medication during pregnancy, according to the European Respiratory Society 3

Poorly controlled asthma poses greater risks to mother and fetus than potential medication risks, as stated by the European Respiratory Society 4
Maintaining good asthma control during pregnancy is critical for maternal and fetal well-being, as recommended by the American Academy of Allergy, Asthma, and Immunology and the European Respiratory Society 4, 1
For moderate persistent asthma, a combination of low-dose ICS and long-acting beta-agonist (LABA) is a preferred treatment option, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
While salmeterol has historically been preferred due to longer experience during pregnancy, continuing formoterol is acceptable if the patient was previously well-controlled, as noted by the European Respiratory Society 3
Use the lowest effective dose necessary to maintain asthma control, as recommended by the European Respiratory Society 3
Regular monitoring of asthma symptoms is recommended throughout pregnancy, according to the American Academy of Allergy, Asthma, and Immunology 1
Exacerbations during pregnancy should be managed aggressively due to potential fetal risks, as stated by the American Academy of Allergy, Asthma, and Immunology 1, 2

For patients already on budesonide/formoterol before pregnancy, continue the medication if asthma is well-controlled, as recommended by the European Respiratory Society and the American Academy of Allergy, Asthma, and Immunology 3, 2
For patients requiring initiation of therapy during pregnancy, consider budesonide as the preferred ICS component, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
If LABA is needed, salmeterol has more pregnancy data but formoterol is acceptable, as noted by the European Respiratory Society 3

Discontinuing asthma medications during pregnancy due to unfounded safety concerns, which can lead to poor asthma control and increased risks to mother and fetus, as warned by the European Respiratory Society 4
Failing to aggressively manage asthma exacerbations during pregnancy, which can lead to maternal hypoxia and adverse fetal outcomes, as stated by the European Respiratory Society 4
Switching from formoterol to salmeterol unnecessarily if the patient was previously well-controlled on formoterol, as cautioned by the European Respiratory Society 3

The American College of Allergy and Clinical Immunology recommends that formoterol is safe to use during pregnancy when needed for asthma control, as the risks of poorly controlled asthma to both mother and fetus substantially outweigh any theoretical medication risks 5
The pharmacologic profile of formoterol is similar to short-acting beta-agonists like albuterol, which have extensive reassuring pregnancy data, suggesting low risk 5

For moderate persistent asthma during pregnancy, the American College of Allergy and Clinical Immunology recommends combination therapy with low-dose inhaled corticosteroid plus long-acting beta-agonist as a preferred treatment option 5
Adding a long-acting beta-agonist to low-dose inhaled corticosteroid provides superior asthma control compared to increasing corticosteroid dose alone, based on evidence from non-pregnant adults 5

The American College of Allergy and Clinical Immunology advises against discontinuing asthma medications during pregnancy due to unfounded safety concerns, and recommends avoiding unnecessarily switching from formoterol to salmeterol if the patient was previously well-controlled on formoterol, and avoiding first-trimester medication exposure when possible, though maintaining control takes priority over timing concerns 5